Anemia Treatment Market - Growth, Trends, and Forecasts (2022 - 2027)

Anemia Treatment Market - Growth, Trends, and Forecasts (2022 - 2027)

The Anemia treatment market is expected to witness robust growth over the forecast period which is majorly attributed to the increasing cases of anemia across the globe, increasing pipelines for anemia drugs, and increasing number of women with reproductive age.

The National Institute of Health has stated that anemia affects around one third of the world population and contributes to increased morbidity and mortality, decreased work productivity, and impaired neurological development. The population which is more vulnerable to this disease is the children below age 5 years and the pregannat women. There are effeorts being made to reduce the burden of this disease. For instance, the WHO Global Nutrition Target 2025 on anemia aims to reduce anemia in WRA by 50% by 2025. Hence, with such efforts, there will be an increase in the number of people going for treatemnt and ultimately the market will grow.

Key Market TrendsIron Deficiency Anemia to Witness Healthy CAGR Over the Forecast Period

Iron deficiency anemia is the most common type of anemia in which the blood does not have adequate amount of reb blood cells which carry oxygen to the body's tissues. As per the National Institute of Health, Iron Deficiency Anemia is one of the main nutritional deficiency disorders affecting large fractions of the population, particularly such physiological groups as children, menstruating women and pregnant women.

Similarly in the Asian countries such as India and China, iron deficiency anemia is posing a burden with increasing prevalence of the disease across the women. Therefore, it is believed that the segment will witness a healthy growth over the forecast period.

North America Dominates the Market

North America dominated the overall anemia treatment market, with the United States being the major contributor to the market. According to the study of Mechanisms of Ageing and Development, 2018, iron deficiency anemia is highly prevalent in pregnant women and children. In the United States, the prevalence rate of iron deficiency anemia was found to be around 10% in women of child bearing age while one third of the children (12 months to 36 months) are likely to suffer from it. Moreover, the increasing product approvals related to anemia treatment are expected to be the major contributor in the market. For instance, recently, Pharmacosmos AS, recieved an US FDA approval for it's product Monoferric for the treatment of iron deficiency anemia. Hence, the high prevalence rate of anemia is expected to boost the growth of the market in North America.

Competitive Landscape

The market for anemia treatment is moderately competitive with a presence of most of the international companies. Companies are focusing on developing the drugs or therapies to treat anemia. Entry to this market is difficult as the company has to go through stringent regulations. However, it is believed that in the future, few small to mid sized companies will be entering in the market and gain a substantial share.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Companies Mentioned
 
Akebia Therapeutics
Bluebird Bio, Inc.
GlaxoSmithKline Plc.
Global Blood Therapeutics, Inc.
Pieris Pharmaceuticals, Inc.
Sanofi
Takeda Pharmaceutical Company
Allergan
Pharmacosmos A/S
Pfizer Inc.
AMAG Pharmaceuticals Inc.

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.